By Sriparna Roy and Sneha S K Jan 28 (Reuters) - Elevance Health said on Wednesday it expects revenue to fall slightly in 2026 and forecast full-year profit below Wall Street estimates, signaling that elevated medical costs will continue to weigh on insurers. The dour outlook ​sent shares of the health insurer down more than 7% before the bell. “We view 2026 as a year of execution and repositioning ‌across Medicaid, Medicare Advantage and (Obamacare plans),” said CEO Gail Boudreaux, adding the forecas ...

Elevance Health forecast 2026 profit below Wall Street expectations on Wednesday, as the health insurer expects higher medical costs to persist into the year. ...

UnitedHealth is reeling from a roughly 20% stock rout after warning investors it expects its first annual revenue decline in more than three decades, a stunning reversal for a company long seen as one of Wall Street’s most reliable growth engines. The selloff wiped tens of billions of dollars off the health-care giant’s market value and sent shockwaves through the broader managed-care sector as investors reassessed the risks in the once‑high‑flying Medicare Advantage business. UnitedHealth’s collapse ac ...

How CFOs Can Keep Balance Sheets Healthy As Medical Costs Climb https://t.co/L6633TUGxy ...

Healthcare Costs - Medical costs for Americans on group insurance are projected to increase by 8.5% [1] - Costs for plans purchased through the Affordable Care Act are also expected to rise [1]

HSA Trends - Older workers typically hold the largest HSA balances [1] - Older workers contribute and withdraw more from HSAs [1] - Medical costs typically grow with age, impacting HSA activity [1]

Core Insights - Centene Corporation is facing significant challenges due to elevated utilization rates and rising medical costs, similar to pressures affecting the broader healthcare industry [1][4] - Membership losses in Medicaid and Medicare Advantage are eroding Centene's base, leading to a decline in stock price and valuation below industry averages [2][4] Valuation and Performance - Centene's forward P/E ratio is 13.25X, lower than the industry average of 16.16X but above its five-year median of 11.24X [3][6] - The stock has decreased by 43.2% year-to-date, underperforming compared to industry peers and the S&P 500 [4] Financial Metrics - Operating expenses increased by 5.5% in 2023, 5.8% in 2024, and surged by 21.1% in the first half of 2025, driven by rising medical costs [7] - The health benefits ratio (HBR) rose from 87.7% in 2023 to 93% in Q2 2025, indicating reduced profitability [7][8] - Adjusted net margin fell from 2.3% to negative 0.2%, with 2025 EPS guidance revised down to $1.75 from $7.25 [8] Debt and Returns - Centene's long-term debt is $17.6 billion, reflecting a debt-heavy balance sheet due to acquisitions [9] - The trailing 12-month return on invested capital is 6.7%, below the industry average of 9% [9] Market Outlook - The Zacks Consensus Estimate for 2025 earnings is $1.64 per share, a 77.1% decrease year-over-year, with eight downward revisions in the past 60 days [11] - Revenue is expected to grow by 16.9% in 2025, despite the challenges [11] Strengths and Opportunities - Centene's commercial business is expanding, with marketplace memberships increasing by 33.2% in Q2 2025 [15] - Medicare quality scores are stable, with a larger portion of members in four-star plans, which qualify for bonus payments [16] Conclusion - Centene's lower valuation may seem attractive, but underlying issues such as rising medical costs, declining memberships, and heavy debt present significant challenges [17] - While there are some positive indicators, they are insufficient to counterbalance the operational and financial headwinds in the near term [17]

Core Insights - Centene Corporation (CNC) reported a second-quarter 2025 adjusted loss per share of 16 cents, missing the Zacks Consensus Estimate of earnings of 68 cents, and a significant decline from the year-ago profit of $2.42 per share [1][11] Financial Performance - The company's revenues increased by 22.4% year over year to $48.7 billion, surpassing the consensus mark by 10.9% [2][11] - Medicaid revenues grew 7% year over year to $21.7 billion, while Medicare revenues surged 58% year over year to $9.5 billion [3] - Commercial revenues improved 18% year over year to $10.1 billion [3] - Total premiums reached $41.7 billion, an 18.8% year-over-year increase, driven by higher premiums and an expanding membership base [4] Membership and Operational Metrics - Total membership (excluding TRICARE) was 28 million as of June 30, 2025, reflecting an 8.9% year-over-year growth, although there were declines in Medicaid and Medicare memberships [6] - The health benefits ratio deteriorated to 93%, a 540 basis point decline year over year, exceeding the consensus mark of 90.82% [7] Expenses and Losses - Operating expenses totaled $49.2 billion, a 27.4% year-over-year increase, attributed to rising medical costs, premium tax expenses, and administrative costs [7] - Adjusted net loss was recorded at $79 million, contrasting with year-ago earnings of $1.3 billion [8] Cash and Equity Position - As of June 30, 2025, Centene had cash and cash equivalents of $14.5 billion, up from $14.1 billion at the end of 2024 [9] - Total assets increased to $86.4 billion from $82.4 billion at the end of 2024, while long-term debt decreased to $17.6 billion from $18.4 billion [9] Share Repurchase Activity - Centene repurchased common shares worth approximately $432 million in the second quarter of 2025 [12] Peer Comparison - Elevance Health, Inc. reported second-quarter 2025 adjusted EPS of $8.84, missing estimates and showing a 12.6% year-over-year decline [13] - UnitedHealth Group is expected to report a significant year-over-year decline in profits despite a projected 12.8% revenue increase [14]

Financial Performance - Elevance Health cut its profit outlook for the year [1] Healthcare Industry Dynamics - Higher medical costs in Affordable Care Act plans impacted Elevance Health [1] - Lower reimbursement from Medicaid impacted Elevance Health [1]

Core Viewpoint - UnitedHealth Group Inc. reported mixed first-quarter 2025 results, with adjusted EPS of $7.20 falling short of estimates, while revenues increased year over year but missed consensus expectations due to lower premiums [1][2]. Financial Performance - Adjusted EPS for Q1 2025 was $7.20, missing the Zacks Consensus Estimate of $7.27, but reflecting a 4.2% year-over-year increase [1]. - Revenues rose 9.8% year over year to $109.58 billion, but missed the consensus mark by 1.4% [1]. - Medical care ratio (MCR) was 84.8%, worsening from 84.3% a year ago and below the consensus estimate of 85.9% [4]. - Total operating costs increased 9.4% year over year to $100.5 billion, exceeding model estimates [5]. - Operating earnings grew 15% year over year to $9.1 billion, with net margin improving from negative 1.4% to 5.7% [6]. Business Segment Performance - UnitedHealthcare revenues increased 12.3% year over year to $84.6 billion, driven by domestic commercial membership growth, surpassing estimates [7]. - Optum revenues were $63.9 billion, up 4.6% year over year, but fell short of the consensus mark [8]. - UnitedHealthcare served 50.1 million members, a 1.9% year-over-year growth, but below the consensus estimate of 50.6 million [9]. Financial Position - Cash and short-term investments rose to $34.3 billion from $29.1 billion at the end of 2024 [10]. - Total assets increased to $309.8 billion from $298.3 billion at the end of 2024 [11]. - Long-term debt decreased to $71.29 billion from $72.36 billion [11]. - Operating cash flows surged to $5.5 billion from $1.1 billion year over year [12]. Capital Deployment - UnitedHealth returned over $5 billion to shareholders through share repurchases and dividends in Q1 2025 [13]. 2025 Outlook - Management revised adjusted net EPS guidance to between $26 and $26.50, down from previous estimates [14]. - Projected net earnings for 2025 are expected to be between $22.5 billion and $23.1 billion, an increase from 2024 [14]. - Revenue estimates for 2025 are between $450 billion and $455 billion, up from $400.3 billion in 2024 [14].